Key result
Targeting metabolic vulnerabilities shared by cancer and CVD may mitigate both cardiotoxicity and tumor progression.
Why the study?
Cancer and cardiovascular disease are intertwined by metabolic changes that promote tumor progression and increase cardiovascular risks, motivating the review of metabolic reprogramming for diagnosis and therapy in cardio-oncology.
Metabolic reprogramming is a shared vulnerability in cancer and cardiovascular disease, offering novel diagnostic and therapeutic targets to mitigate cardiotoxicity and tumor progression in cardio-oncology.
Answers are grounded in this paper and cite their sources.
Highlights potential metabolic targets in cardio-oncology; hypothesis-generating and requires prospective validation before clinical use.
Purpose of the Review In this review article, we present recent conceptual advances in understanding metabolic reprogramming in cancer and CVD and discuss how the assessment of metabolic features using provides opportunities for diagnosis and therapy in cardio-oncology patients. Recent Findings Cardiovascular disease (CVD) and cancer are the two leading causes of morbidity and mortality in the world. Cancer and CVD are intertwined by metabolic changes that promote tumor progression and increase the risk for cardiovascular sequelae. Understanding these interactions has become a focus in “cardio-oncology” to unravel this complex relationship. Several studies demonstrate the consequences of cardiac-specific loss of metabolic activities that can exacerbate cancer-therapy-related toxicities or increase disease progression. Summary Incorporating multi-omics studies with translational models will produce new insights into the relationship between cancer cells and cardiomyocytes at different disease and metabolic states and allow targeted treatments.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2025) conducted a review in Cardiovascular disease and cancer (Cardio-oncology). Metabolic targeting was evaluated. Metabolic reprogramming intertwines cancer and cardiovascular disease, suggesting that targeting metabolic vulnerabilities may offer novel therapeutic strategies to mitigate cardiotoxicity and tumor progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: